Lars Dyrskjøt

The paper identifies atypical B cells (ABCs) as mediators of poor response to BCG immunotherapy in high-risk NMIBC patients, linking their expansion and FCRL5 expression to early recurrence.

This study shows that low T cell receptor diversity in bladder cancer patients is linked to poor outcomes and identifies TCR diversity as a potential biomarker for treatment.

This study identifies the HLA-E/NKG2A axis as a therapeutic target in BCG-unresponsive bladder cancer by showing its role in immune evasion and impaired effector cell function.

UMIseq detects circulating tumor DNA in colorectal cancer patients with high sensitivity and specificity, even at low allele frequencies.

This paper identifies circHIPK3 as a competing endogenous RNA that sequesters IGF2BP2 to regulate target mRNAs, including STAT3, and shows its correlation with bladder cancer survival.

GENIUS transforms multi-omics data into images for deep learning analysis to predict metastatic cancer progression from primary tumors.

The paper shows that alternative splicing of APOBEC3B generates mutagenic and non-mutagenic isoforms, with implications for bladder cancer progression and therapeutic targeting.

The paper identifies circRNA-RBP interactions in cancer, showing their role in circRNA biogenesis and cancer gene expression, with implications for bladder cancer prognosis.